Hikma Pharmaceuticals (LON:HIK) Raised to “Buy” at Berenberg Bank

Berenberg Bank upgraded shares of Hikma Pharmaceuticals (LON:HIK) to a buy rating in a report released on Monday morning, Marketbeat.com reports. Berenberg Bank currently has GBX 2,400 ($31.56) price objective on the stock, up from their prior price objective of GBX 2,100 ($27.61).

Several other research analysts have also recently issued reports on HIK. Barclays reaffirmed an equal weight rating and issued a GBX 2,000 ($26.30) price target on shares of Hikma Pharmaceuticals in a report on Tuesday, May 7th. Deutsche Bank Aktiengesellschaft reissued a buy rating and issued a GBX 2,750 ($36.16) price target on shares of Hikma Pharmaceuticals in a research note on Tuesday, June 18th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of GBX 2,325 ($30.57).

Hikma Pharmaceuticals Stock Performance

HIK opened at GBX 1,977 ($26.00) on Monday. The business has a 50 day moving average price of GBX 1,919.73 and a two-hundred day moving average price of GBX 1,921.21. The company has a debt-to-equity ratio of 55.48, a current ratio of 1.66 and a quick ratio of 1.27. The company has a market capitalization of £4.39 billion, a price-to-earnings ratio of 3,041.54, a price-to-earnings-growth ratio of 2.38 and a beta of 0.40. Hikma Pharmaceuticals has a 1-year low of GBX 1,711 ($22.50) and a 1-year high of GBX 2,165 ($28.47).

Hikma Pharmaceuticals Cuts Dividend

The company also recently announced a dividend, which will be paid on Friday, September 20th. Shareholders of record on Thursday, August 15th will be paid a dividend of $0.32 per share. This represents a yield of 1.37%. The ex-dividend date is Thursday, August 15th. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is currently 9,538.46%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.